,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['trastuzumab', 'breast', 't-dxd', 'trastuzumab deruxtecan', 'bcsm']
phase 3 results support trastuzumab deruxtecan (t-dxd) as a new standard of care for patients with her2-low metastatic #breastcancer, according to a presentation at the conference #asco22. #bcsm
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.